Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

William Timothy Garvey, Rachel Louise Batterham, Meena Bhatta, Silvio Buscemi, Louise N. Christensen, Juan P. Frías, Esteban Jódar, Kristian Kandler, Georgia Rigas, Thomas A. Wadden, Sean Wharton, the STEP 5 Study Group

View at source ↗PDF ↗Article867 citations

Abstract

Abstract The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes. The co-primary endpoints were the percentage change in body weight and achievement of weight loss of ≥5% at week 104. Efficacy was assessed among all randomized participants regardless of treatment discontinuation or rescue intervention. From 5 October 2018 to 1 February 2019, 304 participants were randomly assigned to semaglutide 2.4 mg (n = 152) or placebo (n = 152), 92.8% of whom completed the trial (attended the end-of-trial safety visit). Most participants were female (236 (77.6%)) and white (283 (93.1%)), with a mean (s.d.) age of 47.3 (11.0) years, body mass index of 38.5 (6.9) kg m–2 and weight of 106.0 (22.0) kg. The mean change in body weight from baseline to week 104 was −15.2% in the semaglutide group (n = 152) versus −2.6% with placebo (n = 152), for an estimated treatment difference of −12.6 %-points (95% confidence interval, −15.3 to −9.8; P < 0.0001). More participants in the semaglutide group than in the placebo group achieved weight loss ≥5% from baseline at week 104 (77.1% versus 34.4%; P < 0.0001). Gastrointestinal adverse events, mostly mild-to-moderate, were reported more often with semaglutide than with placebo (82.2% versus 53.9%). In summary, in adults with overweight (with at least one weight-related comorbidity) or obesity, semaglutide treatment led to substantial, sustained weight loss over 104 weeks versus placebo. NCT03693430

Abstract of "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial" by William Timothy Garvey, Rachel Louise Batterham, Meena Bhatta et al., https://doi.org/10.1038/s41591-022-02026-4, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.

Record

Archive ID
doi:10.1038/s41591-022-02026-4
Published
Oct 1, 2022
Venue
Nature Medicine
DOI
10.1038/s41591-022-02026-4
PubMed
36216945
PMC
PMC9556320
Categories
Pharmacology and Obesity Treatment
License
cc-by
Provenance
openalex+europepmc

Topics

Cited in dossiers